Literature DB >> 25185244

Get With The Guidelines AFIB: novel quality improvement registry for hospitalized patients with atrial fibrillation.

William R Lewis1, Jonathan P Piccini2, Mintu P Turakhia2, Anne B Curtis2, Margaret Fang2, Robert E Suter2, Robert L Page2, Gregg C Fonarow2.   

Abstract

BACKGROUND: Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. It is a cause of stroke, heart failure, and death. Guideline-based treatment can improve outcomes in AF. Unfortunately, adherence to these guidelines is low. Get With The Guidelines is a hospital-based performance initiative, which has been shown to improve adherence over time. Get With The Guidelines-AFIB is a novel quality improvement registry designed to improve adherence to AF guidelines. METHODS AND
RESULTS: Hospitals will be recruited by regional American Heart Association staff and key stakeholders. Inpatients or observed patients with AF or atrial flutter will be enrolled. Data collected will include demographic, medical history, and clinical characteristics including laboratory values and treatments. Decision support will guide adherence to achievement and quality measures designed to improve adherence to anticoagulation, heart rate control, safe antiarrhythmic drug use, and patient education and follow-up. Increased adherence to guidelines will be facilitated using rapid-cycle quality improvement, site-specific reporting including national and regional benchmarks and hospital recognition for achievement. Primary analyses will include adherence to American Heart Association/American College of Cardiology performance measures and guidelines. Secondary analyses will include processes of care, risk stratification, treatment of special conditions or populations and use of particular treatment techniques.
CONCLUSIONS: AF is common clinical problem with significant morbidity and mortality. Get With The Guidelines-AFIB is a national hospital-based AF quality improvement program designed to increase adherence to evidence-based guidelines for AF.
© 2014 American Heart Association, Inc.

Entities:  

Keywords:  antiarrhythmia agents; anticoagulants; atrial fibrillation; atrial flutter; quality assurance, health care

Mesh:

Substances:

Year:  2014        PMID: 25185244     DOI: 10.1161/CIRCOUTCOMES.114.001263

Source DB:  PubMed          Journal:  Circ Cardiovasc Qual Outcomes        ISSN: 1941-7713


  15 in total

1.  A Comparison of Oral Anticoagulant Use for Atrial Fibrillation in the Pre- and Post-DOAC Eras.

Authors:  Joshua D Brown; Anand R Shewale; Parinita Dherange; Jeffery C Talbert
Journal:  Drugs Aging       Date:  2016-06       Impact factor: 3.923

2.  Procedural Patterns and Safety of Atrial Fibrillation Ablation: Findings From Get With The Guidelines-Atrial Fibrillation.

Authors:  Zak Loring; DaJuanicia N Holmes; Roland A Matsouaka; Anne B Curtis; John D Day; Nihar Desai; Kenneth A Ellenbogen; Gregory K Feld; Gregg C Fonarow; David S Frankel; Jodie L Hurwitz; Bradley P Knight; Jose A Joglar; Andrea M Russo; Mandeep S Sidhu; Mintu P Turakhia; William R Lewis; Jonathan P Piccini
Journal:  Circ Arrhythm Electrophysiol       Date:  2020-07-23

3.  The Role Of NOACs in Atrial Fibrillation Management: A Qualitative Study.

Authors:  Katherine Kirley; Victoria Bauer; Christopher Masi
Journal:  J Atr Fibrillation       Date:  2016-06-30

4.  Use of Oral Anticoagulation in Eligible Patients Discharged With Heart Failure and Atrial Fibrillation.

Authors:  Nancy Luo; Haolin Xu; Hani Jneid; Gregg C Fonarow; Renato D Lopes; Jonathan P Piccini; Anne B Curtis; Andrea M Russo; William R Lewis; Roland A Matsouaka; Christopher B Granger; Robert J Mentz; Sana M Al-Khatib
Journal:  Circ Heart Fail       Date:  2018-10       Impact factor: 8.790

Review 5.  Measuring quality in electrophysiology.

Authors:  Daniel J Friedman; Sana M Al-Khatib
Journal:  J Interv Card Electrophysiol       Date:  2016-03-03       Impact factor: 1.900

6.  Guideline-directed therapies for comorbidities and clinical outcomes among individuals with atrial fibrillation.

Authors:  Zak Loring; Peter Shrader; Larry A Allen; Rosalia Blanco; Paul S Chan; Michael D Ezekowitz; Gregg C Fonarow; James V Freeman; Bernard J Gersh; Kenneth W Mahaffey; Gerald V Naccarelli; Karen Pieper; James A Reiffel; Daniel E Singer; Benjamin A Steinberg; Laine E Thomas; Eric D Peterson; Jonathan P Piccini
Journal:  Am Heart J       Date:  2019-11-08       Impact factor: 4.749

Review 7.  American Heart Association COVID-19 CVD Registry Powered by Get With The Guidelines.

Authors:  Heather M Alger; Christine Rutan; Joseph H Williams; Jason G Walchok; Michele Bolles; Jennifer L Hall; Steven M Bradley; Mitchell S V Elkind; Fatima Rodriguez; Tracy Y Wang; David A Morrow; Sandeep R Das; James A de Lemos
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2020-06-17

8.  Seasonal Variation of Atrial Fibrillation Admission and Quality of Care in the United States.

Authors:  Shanshan Sheehy; Gregg C Fonarow; DaJuanicia N Holmes; William R Lewis; Roland A Matsouaka; Jonathan P Piccini; Lillian Zhi; Deepak L Bhatt
Journal:  J Am Heart Assoc       Date:  2022-02-12       Impact factor: 6.106

9.  Racial Differences in Atrial Fibrillation-Related Cardiovascular Disease and Mortality: The Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  Jared W Magnani; Faye L Norby; Sunil K Agarwal; Elsayed Z Soliman; Lin Y Chen; Laura R Loehr; Alvaro Alonso
Journal:  JAMA Cardiol       Date:  2016-07-01       Impact factor: 14.676

10.  A prospective multi-site registry of real-world experience of catheter ablation for treatment of symptomatic paroxysmal and persistent atrial fibrillation (Real-AF): design and objectives.

Authors:  Allyson L Varley; Omar Kreidieh; Brigham E Godfrey; Carolyn Whitmire; Susan Thorington; Benjamin D'Souza; Steven Kang; Shrinivas Hebsur; Bipin K Ravindran; Edwin Zishiri; Brett Gidney; Matthew B Sellers; David Singh; Tariq Salam; Mark Metzl; Alex Ro; Jose Nazari; Westby G Fisher; Alexandru Costea; Anthony Magnano; Saumil Oza; Gustavo Morales; Anil Rajendra; Joshua Silverstein; Paul C Zei; Jose Osorio
Journal:  J Interv Card Electrophysiol       Date:  2021-07-02       Impact factor: 1.900

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.